Christensen IJ - Search Results

1

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.

Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünner N. Tarpgaard LS, et al. Among authors: christensen ij. Int J Cancer. 2015 Nov 15;137(10):2470-7. doi: 10.1002/ijc.29476. Epub 2015 Mar 9. Int J Cancer. 2015. PMID: 25664394 Free article. Clinical Trial.

2

Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C. Thorpe SM, et al. Among authors: christensen ij. Cancer Res. 1989 Nov 1;49(21):6008-14. Cancer Res. 1989. PMID: 2790815

3

Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice.

Aabo K, Vindeløv LL, Christensen IJ, Spang-Thomsen M. Aabo K, et al. Among authors: christensen ij. Int J Cancer. 1994 Nov 1;59(3):394-9. doi: 10.1002/ijc.2910590318. Int J Cancer. 1994. PMID: 7927948

4

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. Grøndahl-Hansen J, et al. Among authors: christensen ij. Cancer Res. 1993 Jun 1;53(11):2513-21. Cancer Res. 1993. PMID: 8388317

5

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.

Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Grøndahl-Hansen J, et al. Among authors: christensen ij. Breast Cancer Res Treat. 1997 Apr;43(2):153-63. doi: 10.1023/a:1005744914124. Breast Cancer Res Treat. 1997. PMID: 9131271

6

Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer.

Nielsen HJ, Pappot H, Christensen IJ, Brünner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøndahl-Hansen J. Nielsen HJ, et al. Among authors: christensen ij. BMJ. 1998 Mar 14;316(7134):829-30. doi: 10.1136/bmj.316.7134.829. BMJ. 1998. PMID: 9549453 Free PMC article. No abstract available.

7

Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.

Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, Brünner N. Kos J, et al. Among authors: christensen ij. Clin Cancer Res. 1998 Jun;4(6):1511-6. Clin Cancer Res. 1998. PMID: 9626470

8

Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.

Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N. Grøndahl-Hansen J, et al. Among authors: christensen ij. Clin Cancer Res. 1997 Feb;3(2):233-9. Clin Cancer Res. 1997. PMID: 9815678

9

Serum YKL-40 and colorectal cancer.

Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. Cintin C, et al. Among authors: christensen ij. Br J Cancer. 1999 Mar;79(9-10):1494-9. doi: 10.1038/sj.bjc.6690238. Br J Cancer. 1999. PMID: 10188896 Free PMC article.

10

The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.

Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. Brünner N, et al. Among authors: christensen ij. APMIS. 1999 Jan;107(1):160-7. doi: 10.1111/j.1699-0463.1999.tb01539.x. APMIS. 1999. PMID: 10190293 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

451 results

Search Page